Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04481672 · ClinicalTrials.gov registry record · Phase 1
Intravenous Magnesium in Patients Receiving Cisplatin
A Phase 1 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT04481672 is a Phase 1 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 5 participants.
The verdict
NCT04481672, a Phase 1 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
This research study, is trying to determine the highest dose of magnesium that can be given safely to people with malignant mesothelioma receiving intraoperative chemotherapy with cisplatin who are at risk for acute kidney injury. The name(s) of the study drug involved in this study is * magnesium sulfate.
Interventions
- DRUG Magnesium Sulfate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2021-07-30 |
| Est. Completion | 2021-12-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04481672
The ClinicalTrials.gov registry entry for NCT04481672 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Magnesium Sulfate is the first listed.
NCT04481672 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04481672 about?
NCT04481672 is a clinical study titled "Intravenous Magnesium in Patients Receiving Cisplatin". This research study, is trying to determine the highest dose of magnesium that can be given safely to people with malignant mesothelioma receiving intraoperative chemotherapy with cisplatin who are at risk for acute kidney injury. The name(s) of the study drug involved in this study is * magnesium...
What is the current status of trial NCT04481672?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2021-07-30. Estimated completion is 2021-12-30.
What interventions are being tested in trial NCT04481672?
The interventions under investigation include: Magnesium Sulfate (DRUG).
Who is sponsoring clinical trial NCT04481672?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.